// App-Quantinova.ai

500 : Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies

Researchers

Presenter

  • Andre Schmidt

Principal Investigators

  • Michael Rud Lassen

  • Lorenzo Mantovani

  • Reinhold Kreutz

  • Gerlind Holberg

  • Sylvia Haas

Medical Centers

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Institute of Experimental Oncology and Therapy Research, Technical University Munich, Munich, Germany

  • Spine Center Copenhagen, Copenhagen University Hospital Glostrup, Glostrup, Denmark

  • McMaster University, Hamilton, ON, Canada

  • Faculty of Pharmacy, University of Naples, Naples, Italy

Locations

  • Germany

  • Italy

  • Denmark

  • Canada

Companies

  • Bayer

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Cancer antigen 15-3

Drug/Treatment

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Heparin

Outcome

  • N/A

Study Design

  • open label

  • non interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved